Presentation is loading. Please wait.

Presentation is loading. Please wait.

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis  R. Altman, M.

Similar presentations


Presentation on theme: "Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis  R. Altman, M."— Presentation transcript:

1 Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis  R. Altman, M. Hochberg, A. Kivitz, A. Gibofsky, D. Solorio, C. Young  Osteoarthritis and Cartilage  Volume 24, Pages S419-S420 (April 2016) DOI: /j.joca Copyright © Terms and Conditions

2 Figure 1. Continuous responder analysis of the WOMAC pain subscale scores at week 12 in patients with osteoarthritis. Osteoarthritis and Cartilage  , S419-S420DOI: ( /j.joca ) Copyright © Terms and Conditions


Download ppt "Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis  R. Altman, M."

Similar presentations


Ads by Google